MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyag019

Медицинская библиотека · The oncologist · 2026

Anlotinib in combination with trifluridine-tipiracil in patients with refractory metastatic colorectal cancers: a phase II, single arm study.

Liu Qing, Zhang Chi, Liu Mengling, Peng Ke, Xu Xiaojing, Yu Yiyi, Liu Tianshu

СтатьяКлиническое исследование II фазыПеревод пока не подготовлен

Аннотация

BACKGROUND

The management of metastatic colorectal cancer (mCRC) in late-line settings remains a significant clinical challenge. The SUNLIGHT trial, which investigated the combination of trifluridine-tipiracil (FTD-TPI) and bevacizumab, reported a median progression-free survival (PFS) of 5 months and an objective response rate (ORR) of 6.3%. This phase II study was conducted to evaluate the potential of combining anlotinib with FTD-TPI as a third-line treatment strategy in patients with refractory mCRC.

METHODS

In this open-label, single-arm phase II study, mCRC patients who had experienced disease progression following at least two prior standard treatment regimens were enrolled. Participants received a combination of anlotinib (12 mg, PO, QD, days 1-14, q3w) and FTD-TPI (35 mg/m2, PO, BID, days 1-5, q2w). The primary endpoint was the ORR. Secondary endpoints included disease control rate (DCR), PFS, overall survival (OS) and safety.

RESULTS

As of May 30, 2025, twenty-one patients with mCRC were enrolled in this study. The median age was 62 years, with 71.4% male participants. Among the 20 evaluable patients, 2 achieved a partial response (PR), 16 had stable disease (SD) at the first evaluation. The ORR was 10.0% (2/20), and the DCR reached 90.0% (18/20). Based on Kaplan-Meier estimates, the median PFS was 5.6 months. The most common grade ≥3 treatment emergent adverse event (TEAEs) were neutropenia (25%) and thrombocytopenia (5%).

CONCLUSION

The combination of anlotinib and FTD-TPI demonstrated promising efficacy and a manageable safety profile, supporting its potential as a favorable late-line treatment option for patients with refractory mCRC.

CLINICALTRIALS.GOV IDENTIFIER: ChiCTR2400079535.

Для цитирования: Liu Qing, Zhang Chi, Liu Mengling, Peng Ke, Xu Xiaojing, Yu Yiyi, Liu Tianshu. Anlotinib in combination with trifluridine-tipiracil in patients with refractory metastatic colorectal cancers: a phase II, single arm study.. The oncologist. 2026. DOI: 10.1093/oncolo/oyag019.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.